Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma

详细信息    查看全文

• 作者：Yoshiki Terada (1)
  Hirohisa Nakamae (1)
  Ran Aimoto (1)
  Hiroshi Kanashima (2)
  Erina Sakamoto (2)
  Mizuki Aimoto (1)
  Eri Inoue (1)
  Hideo Koh (1)
  Takahiko Nakane (1)
  Yasunobu Takeoka (1)
  Masahiko Ohsawa (3)
  Ki-Ryang Koh (1)
  Takahisa Yamane (1)
  Yoshitaka Nakao (4)
  Kensuke Ohta (5)
  Atsuko Mugitani (6)
  Hirofumi Teshima (2)
  Masayuki Hino (1)
  
• 刊名：Journal of Experimental & Clinical Cancer Research
• 出版年：2009
• 出版时间：December 2009
• 年：2009
• 卷：28
• 期：1
• 全文大小：426KB
• 参考文献：1. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. / N Engl J Med 1993, 328: 1002-. CrossRef
  2. International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. / N Engl J Med 1993, 329: 987-4. CrossRef
  3. Epelbaum R, Haim N, Ben-Shahar M, Ron Y, Cohen Y: Dose intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. / Isr J Med Sci 1990, 24: 533-.
  4. Kwak LW, Halpern J, Olshen RA, Horning SJ: Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. / J Clin Oncol 1990, 8: 963-7.
  5. Epelbaum R, Faraggi D, Ben-Arie Y, Ben-Shahar M, Haim N, Ron Y, Robinson E, Cohen Y: Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. / Cancer 1990, 66: 1124-. CrossRef
  6. Lepage E, Gisselbrecht C, Haioun C, Sebban C, Tilly H, Bosly A, Morel P, Herbrecht R, Reyes F, Coiffier B: Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol: The GELA (Groupe d'Etude des Lymphomes de l'Adulte). / Ann Oncol 1993, 4: 651-.
  7. Bosly A, Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A, Kaufman L, Dauwe M, Verhoef G: Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. / Ann Hematol 2008, 87: 277-3. CrossRef
  8. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. / N Engl J Med 2002, 346: 235-2. CrossRef
  9. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M, MabThera International Trial Group: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. / Lancet Oncology 2006, 7: 379-1. CrossRef
  10. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Banavida B: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. / Cancer Biother Radiopharm 1997, 12: 177-86. CrossRef
  11. Jaffe ES, Harris NL, Vardiman J, Stein H: Pathology and genetics: neoplasms of the hematopoietic and lymphoid tissues. In / World Health Organization Classification of Tumours. Edited by: Kleihues P, Sobin LH. Lyon: IARC Press; 2001:237-3.
  12. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. / Blood 1994, 84: 1361-2.
  13. McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, Lane M, Gamble JF, Jones SE, Grozea PN, Gutterman J, Coltman C, Moon TE: Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. / Cancer 1976, 38: 1484-3. CrossRef
  14. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CharlesL, Cantor ScottB, Crawford Jeffrey, Cross ScottJ, Demetri George, Desch ChristopherE, Pizzo PhilipA, Schiffer CharlesA, Schwartzberg Lee, Somerfield MarkR, Somlo George, Wade JamesC, Wade JamesL, Winn RodgerJ, Wozniak AntoinetteJ, Wolff AntonioC: 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. / J Clin Oncol 2006, 1: 3187-05. CrossRef
  15. Cox DR: Regression models and life tables (with discussion). / J R Stat Soc B 1972, 34: 187-20.
  16. Lee KW, Kim DY, Yun T, Kim DW, Kim TY, Yoon SS, Heo DS, Bang YJ, Park S, Kim BK, Kim NK: Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: Comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage. / Cancer 2003, 98: 2651-. CrossRef
  17. Vega MI, Huerta-Yepaz S, Garban H, Jazirehi A, Emmanouilides C, Bonavida B: Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. / Oncogene 2004, 23: 3530-0. CrossRef
  18. Alas S, Bonavida B: Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. / Cancer Res 2001, 61: 5137-4.
  19. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI: Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. / Journal of Clin Oncol 2004, 22: 4302-1. CrossRef
  20. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C, European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party: EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. / Eur J Cancer 2006, 42: 2433-3. CrossRef
  21. Pettengell Ruth, Bosly André, Szucs ThomasD, Jackisch Christian, Leonard Robert, Paridaens Robert, Constenla Manuel, Schwenkglenks Matthias: Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. / British Journal of Haematology 2009, 144: 677-85. CrossRef
  22. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trumper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M, German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL): Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). / Lancet Oncol 2008, 9: 105-6. CrossRef
  
• 作者单位：Yoshiki Terada (1)
  Hirohisa Nakamae (1)
  Ran Aimoto (1)
  Hiroshi Kanashima (2)
  Erina Sakamoto (2)
  Mizuki Aimoto (1)
  Eri Inoue (1)
  Hideo Koh (1)
  Takahiko Nakane (1)
  Yasunobu Takeoka (1)
  Masahiko Ohsawa (3)
  Ki-Ryang Koh (1)
  Takahisa Yamane (1)
  Yoshitaka Nakao (4)
  Kensuke Ohta (5)
  Atsuko Mugitani (6)
  Hirofumi Teshima (2)
  Masayuki Hino (1)
  
  1. Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan
  2. Department of Hematology, Osaka City General Hospital, Osaka, Japan
  3. Department of Pathology, Graduate School of Medicine, Osaka City University, Osaka, Japan
  4. Department of Hematology, Wakakoukai Hospital, Osaka, Japan
  5. Department of Hematology, Saiseikai Nakatsu Hospital, Osaka, Japan
  6. Department of Hematology, Seichokai Fuchu Hospital, Osaka, Japan
  
• ISSN：1756-9966

文摘

Background Recently, maintaining higher relative dose intensity (RDI) of chemotherapeutic drugs has become a widespread practice in an attempt to achieve better outcomes in the treatment of aggressive lymphoma. The addition of rituximab to chemotherapy regimens has significantly improved outcome in diffuse large B-cell lymphoma (DLBL). However, it is unknown if higher RDI in chemotherapy when combined with rituximab leads to a better outcome in aggressive B-cell lymphoma. Methods We retrospectively evaluated the impact of the RDI of initial chemotherapy (consisting of cyclophosphamide, doxorubicin, vincristine and prednisolone with rituximab (R-CHOP) on outcome in 100 newly diagnosed DLBL patients. Results A multivariate Cox regression model showed that RDI trended towards a significant association with mortality [hazard ratio per 0.1 of RDI = 0.8; 95% confidence interval 0.6-.0; P = 0.08]. Additionally, on multivariate logistic analysis, advanced age was a significant factor for reduced RDI. Conclusion Our data suggest that in DLBL patients, mortality was affected by RDI of R-CHOP as the initial treatment, and the retention of a high RDI could therefore be crucial.